We found further evidence that a combinatory treatment with PYY3-36 and a GLP-1 agonist (liraglutide) can exert an additive effect on body weight loss similar to that of RYGB, which further underlines their possible usability and efficacy for obesity treatment. This evidence concerns the gene GLP1R and obesity disorder.